Last updated on June 2017

A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder


Brief description of study

A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder

Detailed Study Description

To evaluate the long-term safety of SPD489 administered as a daily morning dose (5, 10, 15, 20, and 30 mg/day) in preschool children diagnosed with Attention-deficit/Hyperactivity Disorder (ADHD). Subjects will be enrolled into this study from antecedent study SPD489-211 (NCT02402166) or SPD489-347.

Clinical Study Identifier: TX149969

Contact Investigators or Research Sites near you

Start Over

Kaley Killdahl

APG Research, LLC
Orlando, FL USA
  Connect »